<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785472</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2315</org_study_id>
    <secondary_id>CLCZ696A2315</secondary_id>
    <nct_id>NCT01785472</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of multiple doses of LCZ696 compared to
      olmesartan in Asian patients with essential hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Office Pulse Pressure (msPP)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Four separate sitting BP measurements should be obtained with a full two minute interval between measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory Blood Pressure</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Successful Blood Pressure Control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful blood pressure control is defined as msSBP &lt;140 mmHg and msDBP &lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ambulatory Pulse Pressure</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Responders are patients with msSBP response (&lt;140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (&lt;90 mmHg or ≥10 mmHg reduction from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1438</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 200 mg tablet</description>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Olmesartan 20 mg capsule</description>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of LCZ696</intervention_name>
    <description>Placebo tablet of LCZ696 200 mg once daily</description>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Olmesartan</intervention_name>
    <description>Placebo capsule of olmesartan 20 mg once daily</description>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild-to-moderate hypertension, untreated or currently taking
             antihypertensive therapy.

          -  Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1)
             must have an msSBP≥150 mmHg and &lt;180 mmHg at the randomization visit (Visit 201) and
             msSBP≥140 mmHg &lt;180 mmHg at the visit immediately preceding Visit 201 (Visit 102 or
             103).

          -  Untreated patients (newly diagnosed with essential hypertension or having a history of
             hypertension but have not been taking any antihypertensive drugs for at least 4 weeks
             prior to Visit 1) must have an msSBP≥150 mmHg and &lt;180 mmHg at both Visit 1 and Visit
             201.

          -  Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and
             the immediately preceding visit.

        Exclusion Criteria:

          -  Patients with severe hypertension (msDBP ≥110 mmHg and or msSBP ≥180 mmHg).

          -  History of angioedema, drug-related or otherwise, as reported by the patient.

          -  History or evidence of a secondary form of hypertension, including but not limited to
             any of the following: renal parenchymal hypertension, renovascular hypertension
             (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary
             hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease,
             and drug-induced hypertension.

          -  Patients who previously entered a LCZ696 study and had been randomized or enrolled
             into the active drug treatment epoch.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koyang</city>
        <state>Kyunggi</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Manila</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan 704</city>
        <state>Taiwan ROC</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei County</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yun-Lin</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rajathevee</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>August 6, 2015</results_first_submitted>
  <results_first_submitted_qc>August 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 200 mg</title>
          <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 400 mg</title>
          <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
        </group>
        <group group_id="P3">
          <title>Olmesartan 20 mg</title>
          <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="479"/>
                <participants group_id="P2" count="473"/>
                <participants group_id="P3" count="486"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="479"/>
                <participants group_id="P2" count="472"/>
                <participants group_id="P3" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
                <participants group_id="P2" count="472"/>
                <participants group_id="P3" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="455"/>
                <participants group_id="P2" count="454"/>
                <participants group_id="P3" count="464"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): All patients who were randomized. Patients were analyzed according to the treatment they were assigned to at the randomization. However, patients who were not qualified for randomization and were inadvertently randomized into the study were excluded from the FAS, provided these patients did not receive study drug</population>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 200 mg</title>
          <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 400 mg</title>
          <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
        </group>
        <group group_id="B3">
          <title>Olmesartan 20 mg</title>
          <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="479"/>
            <count group_id="B2" value="472"/>
            <count group_id="B3" value="484"/>
            <count group_id="B4" value="1435"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="10.17"/>
                    <measurement group_id="B2" value="58.1" spread="9.71"/>
                    <measurement group_id="B3" value="57.4" spread="10.14"/>
                    <measurement group_id="B4" value="57.7" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg</title>
        <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg</title>
          <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements.</description>
          <population>Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.48" spread="0.61"/>
                    <measurement group_id="O2" value="-18.15" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical test was made at a one-sided significance level of 0.025.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>least Square Means net difference</param_type>
            <param_value>-2.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg</title>
        <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg</title>
          <description>Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements</description>
          <population>Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="469"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.67" spread="0.62"/>
                    <measurement group_id="O2" value="-18.15" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg</title>
        <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg</title>
          <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.10" spread="0.37"/>
                    <measurement group_id="O2" value="-8.80" spread="0.38"/>
                    <measurement group_id="O3" value="-6.86" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Office Pulse Pressure (msPP)</title>
        <description>Four separate sitting BP measurements should be obtained with a full two minute interval between measurements.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and endpoint were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Office Pulse Pressure (msPP)</title>
          <description>Four separate sitting BP measurements should be obtained with a full two minute interval between measurements.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and endpoint were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.35" spread="0.42"/>
                    <measurement group_id="O2" value="-12.93" spread="0.43"/>
                    <measurement group_id="O3" value="-11.25" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory Blood Pressure</title>
        <description>In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory Blood Pressure</title>
          <description>In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study.</description>
          <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.07" spread="0.49"/>
                    <measurement group_id="O2" value="-12.76" spread="0.49"/>
                    <measurement group_id="O3" value="-10.26" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.36" spread="0.31"/>
                    <measurement group_id="O2" value="-6.82" spread="0.31"/>
                    <measurement group_id="O3" value="-5.61" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.</title>
        <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.</title>
          <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
          <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.22" spread="16.506"/>
                    <measurement group_id="O2" value="-15.02" spread="14.578"/>
                    <measurement group_id="O3" value="-9.07" spread="17.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.24" spread="20.423"/>
                    <measurement group_id="O2" value="-18.11" spread="15.343"/>
                    <measurement group_id="O3" value="-13.95" spread="19.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.99" spread="19.378"/>
                    <measurement group_id="O2" value="-16.83" spread="16.312"/>
                    <measurement group_id="O3" value="-14.51" spread="18.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.09" spread="19.460"/>
                    <measurement group_id="O2" value="-16.37" spread="18.710"/>
                    <measurement group_id="O3" value="-14.63" spread="18.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.19" spread="19.376"/>
                    <measurement group_id="O2" value="-18.88" spread="16.636"/>
                    <measurement group_id="O3" value="-14.64" spread="21.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.66" spread="16.785"/>
                    <measurement group_id="O2" value="-19.19" spread="17.771"/>
                    <measurement group_id="O3" value="-11.54" spread="21.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.74" spread="21.552"/>
                    <measurement group_id="O2" value="-18.07" spread="19.748"/>
                    <measurement group_id="O3" value="-11.74" spread="24.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.84" spread="17.365"/>
                    <measurement group_id="O2" value="-16.12" spread="16.696"/>
                    <measurement group_id="O3" value="-12.99" spread="20.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.33" spread="16.437"/>
                    <measurement group_id="O2" value="-15.64" spread="18.915"/>
                    <measurement group_id="O3" value="-13.33" spread="18.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.81" spread="17.670"/>
                    <measurement group_id="O2" value="15.13" spread="18.014"/>
                    <measurement group_id="O3" value="-10.89" spread="19.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.98" spread="16.856"/>
                    <measurement group_id="O2" value="-15.93" spread="19.022"/>
                    <measurement group_id="O3" value="-7.66" spread="18.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.99" spread="17.913"/>
                    <measurement group_id="O2" value="-15.54" spread="20.397"/>
                    <measurement group_id="O3" value="-10.51" spread="19.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.46" spread="18.694"/>
                    <measurement group_id="O2" value="-13.28" spread="17.014"/>
                    <measurement group_id="O3" value="-11.49" spread="18.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.64" spread="17.001"/>
                    <measurement group_id="O2" value="-12.33" spread="16.449"/>
                    <measurement group_id="O3" value="-6.66" spread="17.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.73" spread="17.362"/>
                    <measurement group_id="O2" value="-10.12" spread="14.433"/>
                    <measurement group_id="O3" value="-7.81" spread="15.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="14.788"/>
                    <measurement group_id="O2" value="-12.82" spread="13.386"/>
                    <measurement group_id="O3" value="-4.40" spread="15.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.20" spread="15.780"/>
                    <measurement group_id="O2" value="-12.43" spread="14.397"/>
                    <measurement group_id="O3" value="-7.19" spread="14.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.84" spread="15.789"/>
                    <measurement group_id="O2" value="-11.70" spread="13.799"/>
                    <measurement group_id="O3" value="-8.90" spread="14.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.94" spread="12.283"/>
                    <measurement group_id="O2" value="-12.20" spread="15.012"/>
                    <measurement group_id="O3" value="-5.76" spread="16.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.03" spread="19.411"/>
                    <measurement group_id="O2" value="-15.04" spread="14.647"/>
                    <measurement group_id="O3" value="-4.83" spread="15.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.47" spread="16.984"/>
                    <measurement group_id="O2" value="-14.33" spread="13.585"/>
                    <measurement group_id="O3" value="-9.97" spread="16.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.62" spread="17.527"/>
                    <measurement group_id="O2" value="-17.20" spread="14.304"/>
                    <measurement group_id="O3" value="-9.95" spread="18.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.23" spread="20.068"/>
                    <measurement group_id="O2" value="-16.63" spread="15.752"/>
                    <measurement group_id="O3" value="-14.09" spread="25.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.43" spread="15.330"/>
                    <measurement group_id="O2" value="-15.76" spread="17.392"/>
                    <measurement group_id="O3" value="-12.71" spread="15.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.</title>
        <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.</title>
          <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
          <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.93" spread="10.377"/>
                    <measurement group_id="O2" value="-7.38" spread="8.786"/>
                    <measurement group_id="O3" value="-5.99" spread="11.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.47" spread="12.343"/>
                    <measurement group_id="O2" value="-10.19" spread="10.836"/>
                    <measurement group_id="O3" value="-10.49" spread="12.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.24" spread="13.445"/>
                    <measurement group_id="O2" value="-9.90" spread="11.353"/>
                    <measurement group_id="O3" value="-9.28" spread="11.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.86" spread="13.397"/>
                    <measurement group_id="O2" value="-8.65" spread="11.740"/>
                    <measurement group_id="O3" value="-9.80" spread="12.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.27" spread="14.782"/>
                    <measurement group_id="O2" value="-10.79" spread="12.123"/>
                    <measurement group_id="O3" value="-8.54" spread="15.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.83" spread="12.628"/>
                    <measurement group_id="O2" value="-11.47" spread="13.154"/>
                    <measurement group_id="O3" value="-5.55" spread="14.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.15" spread="13.876"/>
                    <measurement group_id="O2" value="-9.13" spread="12.990"/>
                    <measurement group_id="O3" value="-6.23" spread="14.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.00" spread="11.858"/>
                    <measurement group_id="O2" value="-8.90" spread="11.220"/>
                    <measurement group_id="O3" value="-7.44" spread="13.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.88" spread="8.732"/>
                    <measurement group_id="O2" value="-9.56" spread="12.309"/>
                    <measurement group_id="O3" value="-6.83" spread="13.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.89" spread="10.063"/>
                    <measurement group_id="O2" value="-8.14" spread="11.244"/>
                    <measurement group_id="O3" value="-7.07" spread="13.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.22" spread="12.401"/>
                    <measurement group_id="O2" value="-8.69" spread="12.989"/>
                    <measurement group_id="O3" value="-5.41" spread="12.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-402" spread="13.637"/>
                    <measurement group_id="O2" value="-7.39" spread="13.722"/>
                    <measurement group_id="O3" value="-5.64" spread="12.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.84" spread="12.616"/>
                    <measurement group_id="O2" value="-6.33" spread="10.802"/>
                    <measurement group_id="O3" value="-6.69" spread="14.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.34" spread="12.057"/>
                    <measurement group_id="O2" value="-6.73" spread="11.751"/>
                    <measurement group_id="O3" value="-3.97" spread="14.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.53" spread="13.244"/>
                    <measurement group_id="O2" value="-5.51" spread="10.473"/>
                    <measurement group_id="O3" value="-3.85" spread="11.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.91" spread="11.469"/>
                    <measurement group_id="O2" value="-7.20" spread="10.179"/>
                    <measurement group_id="O3" value="-2.60" spread="11.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.68" spread="11.774"/>
                    <measurement group_id="O2" value="-7.21" spread="10.460"/>
                    <measurement group_id="O3" value="-4.43" spread="11.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.87" spread="12.152"/>
                    <measurement group_id="O2" value="-6.94" spread="10.904"/>
                    <measurement group_id="O3" value="-6.36" spread="11.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.32" spread="9.200"/>
                    <measurement group_id="O2" value="-7.61" spread="11.841"/>
                    <measurement group_id="O3" value="-3.94" spread="11.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.17" spread="16.028"/>
                    <measurement group_id="O2" value="-10.45" spread="10.969"/>
                    <measurement group_id="O3" value="-3.06" spread="10.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.97" spread="12.581"/>
                    <measurement group_id="O2" value="-9.44" spread="9.303"/>
                    <measurement group_id="O3" value="-6.33" spread="12.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="11.891"/>
                    <measurement group_id="O2" value="-11.37" spread="10.507"/>
                    <measurement group_id="O3" value="-6.61" spread="12.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.12" spread="13.266"/>
                    <measurement group_id="O2" value="-9.95" spread="10.374"/>
                    <measurement group_id="O3" value="-9.89" spread="15.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.23" spread="10.793"/>
                    <measurement group_id="O2" value="-8.62" spread="10.066"/>
                    <measurement group_id="O3" value="-7.19" spread="10.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.</title>
        <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.</title>
          <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
          <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.29" spread="15.196"/>
                    <measurement group_id="O2" value="-10.38" spread="15.257"/>
                    <measurement group_id="O3" value="-9.37" spread="16.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.51" spread="16.652"/>
                    <measurement group_id="O2" value="-11.07" spread="17.183"/>
                    <measurement group_id="O3" value="-10.26" spread="16.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.03" spread="15.654"/>
                    <measurement group_id="O2" value="-9.82" spread="18.755"/>
                    <measurement group_id="O3" value="-9.10" spread="17.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.79" spread="17.070"/>
                    <measurement group_id="O2" value="-5.77" spread="17.588"/>
                    <measurement group_id="O3" value="-7.55" spread="19.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.84" spread="17.290"/>
                    <measurement group_id="O2" value="-8.15" spread="16.984"/>
                    <measurement group_id="O3" value="-6.40" spread="19.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.71" spread="16.700"/>
                    <measurement group_id="O2" value="-7.77" spread="17.722"/>
                    <measurement group_id="O3" value="-6.51" spread="19.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.07" spread="17.599"/>
                    <measurement group_id="O2" value="-8.27" spread="19.157"/>
                    <measurement group_id="O3" value="-6.93" spread="17.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.07" spread="16.115"/>
                    <measurement group_id="O2" value="-8.30" spread="16.824"/>
                    <measurement group_id="O3" value="-6.36" spread="18.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.31" spread="16.749"/>
                    <measurement group_id="O2" value="-10.65" spread="15.636"/>
                    <measurement group_id="O3" value="-8.70" spread="18.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.48" spread="16.782"/>
                    <measurement group_id="O2" value="-10.68" spread="17.256"/>
                    <measurement group_id="O3" value="-7.55" spread="18.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.01" spread="15.182"/>
                    <measurement group_id="O2" value="-8.96" spread="19.195"/>
                    <measurement group_id="O3" value="-9.49" spread="17.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.37" spread="15.745"/>
                    <measurement group_id="O2" value="-11.55" spread="18.456"/>
                    <measurement group_id="O3" value="-8.25" spread="17.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.49" spread="17.706"/>
                    <measurement group_id="O2" value="10.64" spread="19.736"/>
                    <measurement group_id="O3" value="-9.82" spread="18.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.20" spread="16.747"/>
                    <measurement group_id="O2" value="-13.34" spread="18.467"/>
                    <measurement group_id="O3" value="-10.24" spread="17.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.01" spread="17.729"/>
                    <measurement group_id="O2" value="-11.95" spread="16.789"/>
                    <measurement group_id="O3" value="-12.62" spread="16.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.15" spread="15.683"/>
                    <measurement group_id="O2" value="-14.04" spread="15.090"/>
                    <measurement group_id="O3" value="-12.52" spread="15.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.00" spread="16.145"/>
                    <measurement group_id="O2" value="-14.71" spread="16.069"/>
                    <measurement group_id="O3" value="-11.71" spread="17.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.93" spread="16.180"/>
                    <measurement group_id="O2" value="-15.37" spread="14.999"/>
                    <measurement group_id="O3" value="-9.97" spread="17.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.45" spread="16.800"/>
                    <measurement group_id="O2" value="-16.04" spread="15.968"/>
                    <measurement group_id="O3" value="-10.37" spread="15.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.29" spread="16.220"/>
                    <measurement group_id="O2" value="-14.20" spread="16.727"/>
                    <measurement group_id="O3" value="-10.90" spread="15.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.10" spread="15.413"/>
                    <measurement group_id="O2" value="-15.26" spread="17.307"/>
                    <measurement group_id="O3" value="-10.52" spread="16.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.97" spread="15.504"/>
                    <measurement group_id="O2" value="-12.79" spread="14.252"/>
                    <measurement group_id="O3" value="-10.67" spread="17.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.91" spread="15.622"/>
                    <measurement group_id="O2" value="-9.55" spread="17.616"/>
                    <measurement group_id="O3" value="-10.77" spread="15.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.07" spread="15.572"/>
                    <measurement group_id="O2" value="-11.81" spread="16.006"/>
                    <measurement group_id="O3" value="-7.57" spread="15.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.</title>
        <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.</title>
          <description>Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement</description>
          <population>A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.93" spread="9.153"/>
                    <measurement group_id="O2" value="-6.57" spread="10.350"/>
                    <measurement group_id="O3" value="-4.57" spread="10.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.41" spread="10.593"/>
                    <measurement group_id="O2" value="-551" spread="11.655"/>
                    <measurement group_id="O3" value="-5.49" spread="11.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="11.359"/>
                    <measurement group_id="O2" value="-4.20" spread="12.472"/>
                    <measurement group_id="O3" value="-4.44" spread="12.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="13.107"/>
                    <measurement group_id="O2" value="-3.53" spread="11.966"/>
                    <measurement group_id="O3" value="-4.70" spread="12.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.53" spread="13.159"/>
                    <measurement group_id="O2" value="-3.14" spread="12.208"/>
                    <measurement group_id="O3" value="-3.81" spread="13.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="12.180"/>
                    <measurement group_id="O2" value="-3.55" spread="10.888"/>
                    <measurement group_id="O3" value="-2.94" spread="13.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.85" spread="12.321"/>
                    <measurement group_id="O2" value="-3.31" spread="12.281"/>
                    <measurement group_id="O3" value="-2.71" spread="13.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.07" spread="11.764"/>
                    <measurement group_id="O2" value="-2.22" spread="11.449"/>
                    <measurement group_id="O3" value="-3.44" spread="12.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.34" spread="11.489"/>
                    <measurement group_id="O2" value="-4.78" spread="10.645"/>
                    <measurement group_id="O3" value="-4.54" spread="12.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.53" spread="10.639"/>
                    <measurement group_id="O2" value="-4.48" spread="10.549"/>
                    <measurement group_id="O3" value="-3.57" spread="12.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.53" spread="10.520"/>
                    <measurement group_id="O2" value="-4.10" spread="11.889"/>
                    <measurement group_id="O3" value="-5.51" spread="13.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.43" spread="10.795"/>
                    <measurement group_id="O2" value="-4.42" spread="11.973"/>
                    <measurement group_id="O3" value="-4.50" spread="11.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.57" spread="12.269"/>
                    <measurement group_id="O2" value="-5.01" spread="13.670"/>
                    <measurement group_id="O3" value="-6.04" spread="12.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="12.291"/>
                    <measurement group_id="O2" value="-5.91" spread="12.409"/>
                    <measurement group_id="O3" value="-5.26" spread="12.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.29" spread="12.351"/>
                    <measurement group_id="O2" value="-5.95" spread="11.443"/>
                    <measurement group_id="O3" value="-7.52" spread="12.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.68" spread="12.231"/>
                    <measurement group_id="O2" value="-7.26" spread="10.726"/>
                    <measurement group_id="O3" value="-6.96" spread="11.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.28" spread="12.097"/>
                    <measurement group_id="O2" value="-7.84" spread="11.479"/>
                    <measurement group_id="O3" value="-6.14" spread="12.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.38" spread="11.421"/>
                    <measurement group_id="O2" value="-8.81" spread="10.385"/>
                    <measurement group_id="O3" value="-5.28" spread="12.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.02" spread="11.661"/>
                    <measurement group_id="O2" value="-8.77" spread="10.560"/>
                    <measurement group_id="O3" value="-5.20" spread="11.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.92" spread="11.687"/>
                    <measurement group_id="O2" value="-7.12" spread="10.020"/>
                    <measurement group_id="O3" value="-5.80" spread="11.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.05" spread="10.480"/>
                    <measurement group_id="O2" value="-7.24" spread="12.056"/>
                    <measurement group_id="O3" value="-6.49" spread="12.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.16" spread="10.060"/>
                    <measurement group_id="O2" value="-6.55" spread="8.317"/>
                    <measurement group_id="O3" value="-5.65" spread="11.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.34" spread="10.752"/>
                    <measurement group_id="O2" value="-5.19" spread="11.593"/>
                    <measurement group_id="O3" value="-6.26" spread="9.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.86" spread="9.930"/>
                    <measurement group_id="O2" value="-6.05" spread="9.926"/>
                    <measurement group_id="O3" value="-4.96" spread="9.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Successful Blood Pressure Control</title>
        <description>Successful blood pressure control is defined as msSBP &lt;140 mmHg and msDBP &lt;90 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Successful Blood Pressure Control</title>
          <description>Successful blood pressure control is defined as msSBP &lt;140 mmHg and msDBP &lt;90 mmHg.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256"/>
                    <measurement group_id="O2" value="270"/>
                    <measurement group_id="O3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ambulatory Pulse Pressure</title>
        <description>Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ambulatory Pulse Pressure</title>
          <description>Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.78" spread="0.23"/>
                    <measurement group_id="O2" value="-5.98" spread="0.23"/>
                    <measurement group_id="O3" value="-4.58" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders</title>
        <description>Responders are patients with msSBP response (&lt;140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (&lt;90 mmHg or ≥10 mmHg reduction from baseline)</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>Responders are patients with msSBP response (&lt;140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (&lt;90 mmHg or ≥10 mmHg reduction from baseline)</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="314"/>
                    <measurement group_id="O3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability</title>
        <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Safety Set (SAF): All patients who received at least one dose of double-blind trial medication. Patients were analyzed according to the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability</title>
          <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
          <population>Safety Set (SAF): All patients who received at least one dose of double-blind trial medication. Patients were analyzed according to the treatment they received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="472"/>
                <count group_id="O3" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (non-serious and serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 200 mg</title>
          <description>Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 400 mg</title>
          <description>Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.</description>
        </group>
        <group group_id="E3">
          <title>Olmesartan 20 mg</title>
          <description>Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="472"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

